Healthcare · NIFTY 500

Mankind Pharma Limited

NSEMANKIND BSE543904 ISININE634S01028 SeriesEQ Listed on NSE · BSE

₹2,638.60 -21.40 (-0.80%) Updated 12 Nov, 8:49 pm IST

Open chart Back to screener

Price, daily close+7.20% in a year

Today

Open: ₹2,660.00
Prev close: ₹2,660.00
Day high: ₹2,667.90
Day low: ₹2,631.20
Volume: 4.24 L
Value traded: ₹112.13 Cr
Upper circuit: ₹2,713.40
Lower circuit: ₹2,555.40
52W high: ₹2,642.00
52W low: ₹1,909.70
1 month: +6.72%
6 months: +2.88%

52W low52W high

Ratios

Key numbers

Worked out from the latest filings (Consolidated) and today's price. TTM = last four quarters.

Market cap₹108,974 Cr

P/E (TTM)48.65

P/B6.20

Book value / share₹425.72

EPS (TTM)₹54.24

ROE12.8%

Dividend yield—

Dividend (12m)—

Net margin (TTM)14.6%

Operating margin27.0%

Debt / equity0.31

Current ratio1.37

EV / EBITDA28.70

Sales growth (YoY qtr)+17.33%

Profit growth (YoY qtr)+39.09%

Sales CAGR 3Y+17.73%

Profit CAGR 3Y+14.28%

Shares41.30 Cr

Quarterly results

Results for each quarter

Last 12 quarters, consolidated, ₹ crore. Hover a bar to see the number.

Revenue and net profit

2,708501

Sep 23

2,607454

Dec 23

2,441471

Mar 24

2,893536

Jun 24

3,077653

Sep 24

3,230380

Dec 24

3,570438

Jun 25

3,697512

Sep 25

3,567409

Dec 25

3,443554

Mar 26

4,031574

Jun 26

4,338711

Sep 26

Revenue · QoQ (vs last quarter)

—-3.7%-6.4%+19%+6.3%+5.0%—+3.6%-3.5%-3.5%+17%+7.6%

Revenue · YoY (vs a year ago)

————+14%+24%+23%+20%+10%—+13%+17%

Net profit · QoQ (vs last quarter)

—-9.4%+3.9%+14%+22%-42%—+17%-20%+36%+3.6%+24%

Net profit · YoY (vs a year ago)

————+30%-16%-18%-22%+7.5%—+31%+39%

RevenueNet profitLine = trend

12.49

Sep 23

11.31

Dec 23

11.74

Mar 24

13.37

Jun 24

16.28

Sep 24

9.44

Dec 24

10.60

Jun 25

12.38

Sep 25

9.89

Dec 25

13.41

Mar 26

13.74

Jun 26

17.20

Sep 26

EPS (₹) · YoY (vs a year ago)

————+30%-17%-21%-24%+4.8%—+30%+39%

EPS (₹)Line = trend

₹ Cr	Sep 23	Dec 23	Mar 24	Jun 24	Sep 24	Dec 24	Jun 25	Sep 25	Dec 25	Mar 26	Jun 26	Sep 26
Revenue	2,708	2,607	2,441	2,893	3,077	3,230	3,570	3,697	3,567	3,443	4,031	4,338
Other income	60.0	70.1	92.1	101	109	77.3	79.9	91.9	72.8	114	45.0	94.9
Total income	2,768	2,677	2,533	2,994	3,186	3,307	3,650	3,789	3,640	3,557	4,076	4,433
Raw material	474	457	436	473	462	536	586	594	553	555	685	675
Purchases	363	353	342	433	424	387	405	413	412	498	547	548
Employee cost	572	568	582	634	646	710	783	825	824	752	914	949
Other expenses	629	605	531	765	705	755	887	888	846	803	963	1,013
Total expenses	2,131	2,119	1,964	2,330	2,339	2,813	3,113	3,167	3,028	2,878	3,310	3,507
Operating profit	683	607	591	682	850	830	847	921	813	907	1,056	1,171
OPM %	25.2%	23.3%	24.2%	23.6%	27.6%	25.7%	23.7%	24.9%	22.8%	26.3%	26.2%	27.0%
Finance cost	8.6	9.2	9.4	10.9	7.1	221	171	170	157	142	110	105
Depreciation	96.5	110	105	108	106	192	219	222	223	223	226	236
Exceptional items	—	—	—	—	—	—	—	—	-107	-23.2	—	—
Profit before tax	638	558	569	664	847	494	537	622	506	656	766	925
Tax	130	103	95.0	125	190	113	95.9	104	95.1	99.8	195	213
Net profit	511	460	477	543	659	385	445	520	414	559	574	716
Profit to shareholders	501	454	471	536	653	380	438	512	409	554	—	711
EPS (₹)	12.49	11.31	11.74	13.37	16.28	9.44	10.60	12.38	9.89	13.41	13.74	17.20

Profit & loss

Results for each year

4 financial years (April to March), consolidated, ₹ crore.

Sales, operating profit and net profit

8,7491,9011,282

FY23

10,3352,5351,913

FY24

12,2073,0181,986

FY25

14,2783,4881,913

FY26

Revenue · YoY (vs a year ago)

—+18%+18%+17%

Net profit · YoY (vs a year ago)

—+49%+3.8%-3.7%

RevenueOperating profitNet profitLine = trend

₹ Cr	FY23	FY24	FY25	FY26
Revenue	8,749	10,335	12,207	14,278
Other income	129	281	537	359
Total expenses	7,219	8,231	10,240	12,186
Employee cost	1,918	2,275	2,692	3,184
Operating profit	1,901	2,535	3,018	3,488
OPM %	21.7%	24.5%	24.7%	24.4%
Finance cost	44.5	33.5	429	639
Depreciation	326	398	621	886
Profit before tax	1,659	2,384	2,504	2,321
Tax	362	458	510	395
Tax rate %	21.8%	19.2%	20.4%	17.0%
Net profit	1,310	1,942	2,011	1,938
Profit to shareholders	1,282	1,913	1,986	1,913
Net margin %	14.7%	18.5%	16.3%	13.4%
EPS (₹)	32.00	47.68	49.19	46.28

Balance sheet

Assets and debt

At each year end (and the latest half year), ₹ crore.

Equity, debt and assets

7,435170305

Mar 23

9,363207382

Mar 24

14,3328,511407

Mar 25

16,3006,312392

Mar 26

17,5825,4221,114

Sep 26

Shareholders' equity · YoY (vs a year ago)

—+26%+53%+14%—

Shareholders' equityBorrowingsCashLine = trend

₹ Cr	Mar 23	Mar 24	Mar 25	Mar 26	Sep 26
Shareholders' equity	7,435	9,363	14,332	16,300	17,582
Long-term borrowings	28.3	32.6	5,540	2,893	3,101
Short-term borrowings	142	175	2,971	3,419	2,320
Total borrowings	170	207	8,511	6,312	5,422
Current liabilities	1,863	2,120	5,664	6,507	5,885
Fixed assets (PPE)	2,524	2,932	2,908	2,960	3,037
Inventories	1,498	1,553	2,094	2,144	2,345
Trade receivables	576	848	1,538	1,730	2,179
Cash & equivalents	305	382	407	392	1,114
Current assets	4,427	6,648	7,175	7,140	8,069
Total assets	9,715	11,963	27,760	28,080	28,954
Debt / equity	0.02	0.02	0.59	0.39	0.31

Cash flow

Cash coming in and going out

For each financial year, ₹ crore. Free cash flow = cash from operations minus spending on fixed assets.

Operating, investing and financing cash

1,813-1,054-740

FY23

2,152-2,0825.3

FY24

2,413-12,68310,290

FY25

3,121-196-2,953

FY26

Operations · YoY (vs a year ago)

—+19%+12%+29%

OperationsInvestingFinancingLine = trend

₹ Cr	FY23	FY24	FY25	FY26
Cash from operations	1,813	2,152	2,413	3,121
Cash from investing	-1,054	-2,082	-12,683	-196
Cash from financing	-740	5.3	10,290	-2,953
Spent on fixed assets	-789	-315	-461	-626
Free cash flow	1,024	1,837	1,953	2,495
Net cash flow	19.4	76.0	20.6	-27.8

Shareholding

Who holds the shares

Promoter and public holding at each quarter end, as filed with NSE.

Holding over time

74.9%Mar 24

74.9%Jun 24

74.9%Sep 24

72.7%Dec 24

72.7%Mar 25

72.7%Jun 25

72.7%Sep 25

72.7%Dec 25

72.7%Mar 26

72.6%Jun 26

72.6%Sep 26

Promoter & groupPublic

Latest (30 Sep 2026)

72.6%promoter

Promoter & group: 72.62%
Public (FIIs, mutual funds, retail…): 27.38%
Promoter change, last quarter: -0.01 pts

Dividends & news

Latest dividends and announcements

Dividends & corporate actions

Interim Dividend - Re 1 Per ShareEx 08-Aug-2025

Board meetings

MANKIND PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 26-Oct-2026 to inter-alia consider and approve the Unaudited Finan…26-Oct-2026
the financial results for the period ended September 30, 202626-Oct-2026
MANKIND PHARMA LIMITED has informed the Exchange about Board Meeting to be held on 30-Jul-2026 to inter-alia consider and approve the Unaudited Finan…30-Jul-2026
the financial results for the period ended Jun 30, 202630-Jul-2026
the Yearly Audited Financial results of the Company for the period ended March 2026 and Alteration of form or nature or rights of securities.19-May-2026

Filings with NSE

Analysts/Institutional Investor Meet/Con. Call Updates6 Nov
General Updates5 Nov
Analysts/Institutional Investor Meet/Con. Call Updates3 Nov
Analysts/Institutional Investor Meet/Con. Call Updates30 Oct
Credit Rating29 Oct
Investor Presentation27 Oct
Copy of Newspaper Publication27 Oct

Latest news

Mankind Pharma Share Price - Live NSE: MANKIND Stock Price & ChartUpstox · 10 Nov, 1:17 am Mankind Pharma shares get an upgrade from Kotak; Price target among top five on the street - CNBC TV18LinkedIn · 21 Sep, 12:30 pm Mankind Pharma stock surges 4.5% as Q2 profit jumps 39%, revenue rises 17%Moneycontrol.com · 26 Oct, 12:30 pm Mankind Pharma Stock Gains As Kotak Upgrades Stock To ‘Buy’, Raises Target To Rs 3,000TradingView · 22 Sep, 12:30 pm Pharma shares shine: Sai, Gland, Divi's, Laurus, Glenmark surge up to 9%Business Standard · 9 Nov, 12:23 pm Mankind Pharma shares get an upgrade from Kotak; Price target among top five on the streetCNBC TV18 · 22 Sep, 12:30 pm Mankind Pharma shares jump 2% as Morgan Stanley initiates coverage with Overweight call. Check target, upsThe Economic Times · 27 Mar, 12:30 pm Mankind Pharma Share Price Falls Over 5% Even As Q1 Profit Rises 29%NDTV Profit · 31 Jul, 12:30 pm

About

About Mankind Pharma Limited

Mankind Pharma Limited is listed on the NSE under the symbol MANKIND and belongs to the Healthcare sector.

BRANDS

ManforcePrega News

Company details

Company name: Mankind Pharma Limited
NSE symbol: MANKIND
BSE scrip code: 543904
ISIN: INE634S01028
Listed on: NSE, BSE
Series: EQ (normal equity)
Listed on NSE since: 9 May 2023
Face value: ₹1 per share
Market lot: 1 share
Shares issued: 41.30 crore
Index: NIFTY 500
Sector (NSE): Healthcare
Industry: Pharmaceuticals: Major
Managing director / CEO: Sheetal Arora
Chair: Ramesh Juneja
Headquarters: New Delhi, Delhi, India
Registered address: 262, Okhla Industrial Estate, Phase-III, New Delhi, 110020, India
Founded: 1991
Employees: 27,000
Financial year: April to March
Results basis: Consolidated
Website: mankindpharma.com

Peers

Other Healthcare stocks

Prices from NSE via Upstox. Financials from the company's results filed with NSE (XBRL); ratios are our own working. Profile from global-stock-logos (MIT). For information only, not a recommendation to buy or sell.

India, Wall Street, crypto and commodities, live.

Every product, one clear workflow.

Built from data, on the record.

A clearer view of the markets.

Calculators and tools that show the maths.

Read the numbers, not the noise.

Mankind Pharma Limited

Today

Ratios

Quarterly results

Revenue and net profit

Profit & loss

Sales, operating profit and net profit

Balance sheet

Equity, debt and assets

Cash flow

Operating, investing and financing cash

Shareholding

Holding over time

Latest (30 Sep 2026)

Dividends & news

Dividends & corporate actions

Board meetings

Filings with NSE

Latest news

About

Company details

Peers